Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

Elsayed Z. Soliman, Jens D. Lundgren, Mollie P. Roediger, Daniel A. Duprez, Zelalem Temesgen, Markus Bickel, Judith C. Shlay, Charurut Somboonwit, Peter Reiss, James H. Stein, James D. Neaton

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

Background: There are contradictory reports regarding the effects of protease inhibitors on the ECG measures of QT and PR interval durations. The effect of interrupting use of protease inhibitors on QT and PR progression is also unknown. Methods: This analysis included 3719 participants from the Strategies for Management of Antiretroviral Therapy (SMART) study, of whom 1879 were randomized to receive intermittent antiretroviral therapy (ART) (drug conservation group), whereas the rest received these drugs continuously (viral suppression group). Linear regression analysis was used to compare four ritonavir-boosted protease inhibitor (protease inhibitor/r) regimens [saquinavir (SQV/r), lopinavir (LPV/r), atazanavir (ATV/r), and other protease inhibitor/r], and nonboosted protease inhibitor regimens with nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens for Bazett's (QTcB) and Fredericia's (QTcF) heart rate corrected QT and PR. Changes in QTcB, QTcF, and PR after 12 and 24 months of randomization were compared in the drug conservation group and viral suppression group. Results: Average levels of QTcB, QTcF, and PR duration at entry were 415, 406, and 158 ms. At study entry, 49% of participants were taking an NNRTI (no protease inhibitor)-based regimen and 31% were prescribed a boosted protease inhibitor, the most common being LPV/r. After adjustment for baseline factors, QTcB and QTcF levels did not vary by boosted protease inhibitor group (P = 0.26 and P = 0.34, respectively). For those given any of the boosted protease inhibitors, QTcB was 1.5 ms lower than the NNRTI group (P = 0.04). Both boosted and nonboosted protease inhibitor-containing regimens were significantly associated (P < 0.01 for each) with longer PR intervals compared to the NNRTI group. After adjustment, the difference between boosted protease inhibitors and the NNRTI group was 5.11 ms (P < 0.01); for nonboosted protease inhibitors, this difference was 3.00 ms (P < 0.01). Following ART interruption, PR duration declined for both the boosted and nonboosted protease inhibitor groups and compared to the viral suppression group, significant changes in PR interval were observed 24 months after ART interruption of boosted protease inhibitors (P < 0.01). Conclusion: Different protease inhibitor-based regimens have a similar, minimal effect on QT compared to NNRTI-based regimens. All protease inhibitor-based regimens (boosted and nonboosted) were associated with prolongation of PR, and interruption of protease inhibitor regimens reduced the prolonged PR duration. Further research is needed to confirm the findings of this study and assess the clinical relevance of the differences.

Original languageEnglish (US)
Pages (from-to)367-377
Number of pages11
JournalAIDS
Volume25
Issue number3
DOIs
StatePublished - Jan 28 2011

Keywords

  • HIV/AIDS
  • PR
  • QTc
  • electrocardiogram
  • protease inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations'. Together they form a unique fingerprint.

  • Cite this

    Soliman, E. Z., Lundgren, J. D., Roediger, M. P., Duprez, D. A., Temesgen, Z., Bickel, M., Shlay, J. C., Somboonwit, C., Reiss, P., Stein, J. H., & Neaton, J. D. (2011). Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS, 25(3), 367-377. https://doi.org/10.1097/QAD.0b013e328341dcc0